



## **The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer**

Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling,  
Marc J. Vijver, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken  
Peeters, Harm Tinteren, Laura J. Van'T Veer, Sjoerd Rodenhuis

### **► To cite this version:**

Marieke E. Straver, Annuska M. Glas, Juliane Hannemann, Jelle Wesseling, Marc J. Vijver, et al.. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. *Breast Cancer Research and Treatment*, 2009, 119 (3), pp.551-558. 10.1007/s10549-009-0333-1 . hal-00535339

**HAL Id: hal-00535339**

**<https://hal.science/hal-00535339>**

Submitted on 11 Nov 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

Marieke E. Straver · Annuska M. Glas · Juliane Hannemann · Jelle Wesseling ·  
Marc J. van de Vijver · Emiel J. Th. Rutgers · Marie-Jeanne T. F. D. Vrancken Peeters ·  
Harm van Tinteren · Laura J. van't Veer · Sjoerd Rodenhuis

Received: 27 January 2009 / Accepted: 29 January 2009 / Published online: 13 February 2009  
© Springer Science+Business Media, LLC. 2009

**Abstract** The 70-gene signature (MammaPrint™) is a prognostic tool used to guide adjuvant treatment decisions. The aim of this study was to assess its value to predict chemosensitivity in the neoadjuvant setting. We obtained the 70-gene profile of stage II–III patients prior to neoadjuvant chemotherapy and classified the prognosis-signatures. Pathological complete remission (pCR) was used to measure chemosensitivity. Among 167 patients, 144 (86%) were having a poor and 23 (14%) a good

prognosis-signature. None of the good prognosis-signature patients achieved a pCR (0/23), whereas 29/144 patients (20%) in the poor prognosis-signature group did ( $P = 0.015$ ). All triple-negative tumors ( $n = 38$ ) had a poor prognosis-signature. Within the non triple-negative subgroup, the response of the primary tumor remained associated with the classification of the prognosis-signature ( $P = 0.023$ ). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy.

M. E. Straver · E. J. Th. Rutgers ·  
M.-J. T. F. D. Vrancken Peeters  
Department of Surgical Oncology, The Netherlands Cancer  
Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,  
1066 CX Amsterdam,  
The Netherlands

M. E. Straver  
e-mail: m.straver@nki.nl

A. M. Glas · L. J. van't Veer  
Agendia BV, Science Park 406, 1098 XH Amsterdam,  
The Netherlands

J. Hannemann · J. Wesseling · M. J. van de Vijver ·  
L. J. van't Veer  
Department of Pathology, The Netherlands Cancer  
Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,  
1066 CX Amsterdam, The Netherlands

H. van Tinteren  
Department of Biometrics, The Netherlands Cancer  
Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,  
1066 CX Amsterdam, The Netherlands

S. Rodenhuis (✉)  
Department of Medical Oncology, The Netherlands Cancer  
Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,  
1066 CX Amsterdam, The Netherlands  
e-mail: s.rodenhuis@nki.nl

**Keywords** Breast cancer · Neoadjuvant ·  
Chemosensitivity · Predictive · Gene expression signature

## Introduction

The mortality of breast cancer is decreasing in the developed part of the world. This is largely a result of effective adjuvant systemic therapy [1]. An important problem of adjuvant therapy is overtreatment, which consists of the administration of adjuvant therapy in patients for whom surgical resection of the tumor alone would be curative. These patients will experience toxicity without benefiting from the treatment. Currently, the selection of patients for adjuvant treatment is based on tumor and patients characteristics such as endocrine responsiveness, tumor grade, lymph node status and age. One strategy to reduce overtreatment is the use of prognostic biomarkers. Systematic analysis of gene-expression patterns using microarray technology has led to the discovery of prognostic gene-expression signatures, one of which is the 70-gene prognostic-signature (MammaPrint™) [2].

The prognostic value of 70-gene profile has been validated in a range of series of patients [3–6]. These studies

confirmed that the 70-gene signature accurately discriminates between patients at high risk of distant metastasis and death and patients with a favorable prognosis. Furthermore, it was shown that the 70-gene signature adds independent prognostic information to that provided by commonly used clinicopathological factors.

Node-negative patients with a good prognosis-signature who did not receive any adjuvant systemic therapy, had a 10-year overall survival of 89% (95%CI 0.81–0.94). These results suggest that adjuvant therapy could be limited to endocrine treatment for tumors with a good prognosis-signature. At present, the MINDACT trial is addressing this question. In this trial, treatment selection based on the 70-gene signature as compared to clinical risk assessment, may show that it does not compromise the overall outcome [7].

Virtually all (92–98%) of the good prognosis-signature tumors show a high expression of the estrogen receptor (ER). Furthermore, tumors with a good prognosis signature are usually those with lower proliferative rates. It is, therefore, often assumed that good prognosis-signature tumors may be less sensitive to chemotherapy than tumors with a poor prognosis-signature. If true, the 70-gene signature would have predictive power in addition to its prognostic value.

To analyze the predictive value of the 70-gene profile, we determined the 70-gene signature in tumors of patients treated with neoadjuvant chemotherapy at The Netherlands Cancer Institute. The objectives of this study were: (1) to analyze the association between the pathological complete response (pCR) rate and the results of the prognostic signature test, and (2) to assess the predictive value in different subgroups defined by the expression of hormone receptors and the amplification of the human epidermal growth factor receptor 2 (HER2) genes.

## Methods

### Patients

Fresh frozen tumor biopsies and clinical data were collected from a consecutive series of 171 patients who received neoadjuvant chemotherapy at The Netherlands Cancer Institute between 2000 and 2008. Patients received neoadjuvant chemotherapy in one of two clinical studies ongoing or received treatment according to the standard arm of these trials [8]. Patients with invasive breast cancer greater than 3 cm and/or involved lymph nodes were eligible for these studies. The clinical studies were approved by the institutional ethical committee and informed consent was obtained from all patients. Prior to neoadjuvant treatment, 14-gauge biopsies of the breast tumor were taken under ultrasound guidance. These biopsies were snap-frozen in liquid

nitrogen and stored at  $-70^{\circ}\text{C}$ . All patients of whom adequate RNA could be extracted from the tumor samples were included in the study, provided that they had undergone surgery to determine the pathological remission status.

### Clinicopathological data

Clinical data were collected from medical records, blinded to the 70-gene prognosis-signature. Tumor size was assessed by MRI ( $n = 155$ ) when available or by mammogram and ultrasound examination ( $n = 16$ ). Nodal status prior to neoadjuvant chemotherapy was determined by ultrasound guided fine-needle aspiration or, when negative sentinel node biopsy. In 16 patients with inconclusive cytological assessment the pathological nodal status prior to neoadjuvant chemotherapy remained unknown. Tumor grading was defined according to the Elston and Ellis method [9]. Estrogen receptor (ER) status and progesterone receptor status were determined by immunohistochemistry and interpreted positive if more than 10% of the nuclei stained positive. HER2 status was assessed by scoring the intensity of membrane staining using immunohistochemistry. Tumors with a score of 3+ (strong homogeneous staining) were considered HER2-positive. In case of 2+ scores (moderate homogeneous staining) chromogenic in situ hybridization (CISH) was used to determine amplification [10]. Amplification was defined as a gene copy number of over five per cell. Tumors were classified in three subgroups according to their receptor status using immunohistochemical staining; (1) ER-positive and HER2-negative tumors, (2) triple negative tumors (ER-negative, PR-negative and HER2-negative) and (3) HER2-positive tumors.

The treatment regimen depended on the presence or absence of HER2 amplification. Preoperative chemotherapy for HER2-negative tumors employed one of the following regimens: AC (six cycles of doxorubicin  $60\text{ mg/m}^2$  and cyclophosphamide  $600\text{ mg/m}^2$ , q 3 weeks); dose dense (dd) AC (AC q 2 weeks with filgrastim) [11]; AD (six cycles of doxorubicin  $50\text{ mg/m}^2$  and docetaxel  $75\text{ mg/m}^2$ ) or DC (six cycles of docetaxel  $75\text{ mg/m}^2$  and capecitabine  $2 \times \text{dd } 1,000\text{ mg/m}^2$  orally during 14 days, q 3 weeks) [12, 13]. For HER2-positive tumors, the regimens included ddAC and PTC (paclitaxel  $80\text{ mg/m}^2\text{ week}^{-1}$ , trastuzumab  $2\text{ mg/kg}$  and carboplatin AUC 2–3  $\text{mg/ml min times } 6, \text{ q } 8\text{ weeks}$ ) after 2005 [14, 15]. After one or three cycles (depending on the specific protocol) the tumor response was evaluated by contrast enhanced MRI [16]. Chemotherapy regimens were changed to a presumably non-cross-resistant regimen when response failure was apparent upon radiological evaluation. After the last course of chemotherapy patients underwent mastectomy or breast conserving surgery. Three patients had progressive disease. In two patients, surgery was performed prior to the completion of chemotherapy and one

patient with mastitis carcinomatosa was treated with radiation therapy only. To prevent bias, these patients were kept in the analysis despite the fact that they underwent early or no surgery.

#### RNA extraction and gene expression analysis

RNA isolation and amplification were performed as previously described [17]. One 5- $\mu$ m tissue section of the biopsy was hematoxylin and eosin stained to monitor the tumor cell percentage of the tissue. Only specimens with at least 50% tumor cells were further analyzed. To assess the mRNA expression level of the 70 genes, RNA was hybridized to a custom-designed array (MammaPrint™, FDA 510(K) cleared), blinded to clinical data, at Agendia's ISO17025-certified and CLIA accredited laboratories. Tumors were classified as good prognosis-signature (low risk) or poor prognosis signature (high risk) as described previously [18].

#### Assessment of tumor response

Pathological complete response (pCR) was used as the outcome measure. It was defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ [19]. Furthermore, the response of the primary tumor in the breast was assessed separately. The response of the primary tumor was defined as a pCR when no residual tumor cells were seen at microscopy or as a 'near pCR' (npCR) when small numbers of scattered tumor cells or tumor cells in an area of less than 2 mm in diameter were present.

#### Statistical analysis

Analyses were performed using SPSS version 15.1 (SPSS Inc, Chicago, IL). The differences in patients and tumor characteristics between the 70-gene poor and good prognosis signature were tested using Fisher's Exact test and students t test. We used the Fisher's Exact test to assess the association between the response of the tumor and the outcome of the 70-gene profile. Disease-free survival curves were calculated using the Kaplan–Meier method and compared using the log-rank test. *P*-values reported are two sided.


#### Results

The 70-gene profile was analyzed in 171 patients who received neoadjuvant chemotherapy. Three of these 171 patients were excluded due to clinical reasons. Two

patients did not undergo surgery of the primary tumor and in one patient the treatment with chemotherapy was discontinued early due to major toxicity. In one patient the RNA quality was insufficient to perform gene profiling. Thus, the predictive value of the 70-gene prognostic signature could be evaluated in 167 patients. (Fig. 1).

Patient and tumor characteristics are presented in Table 1. Among the 167 patients, 23 (14%) had a good prognosis-signature, whereas 144 (86%) patients had a poor prognosis-signature. Tumors with a poor prognosis-signature were of higher grade, and were more often classified as triple-negative or HER2 positive tumors. Consequently, more patients in the poor prognosis-signature group were treated with a trastuzumab based regimen.

The overall pCR rate (absence of invasive tumor in both breast and axilla) was 17% (29/167). None of the patients with a good prognosis-signature achieved a pCR (0/23). The pCR rate in the poor prognosis-signature group was



**Fig. 1** The patients selection and the classification of the 70-gene signature. The pathological response in breast and axilla is determined for both risk groups. A poor prognosis profile was significantly associated with the pathological complete remission (pCR) of both the breast and axilla ( $P = 0.015$ ) and with response (near pCR or pCR) of the primary tumor separately ( $P = 0.008$ )

**Table 1** The patient and tumor characteristics and the association with the 70-gene signature

	Total <i>n</i> = 167 No. (%)	Good prognosis <i>n</i> = 23 No. (%)	Poor prognosis <i>n</i> = 144 No. (%)	<i>P</i> value
Mean age	46	46	46	NS
Range	23–68	31–58	23–68	
Menopausal status				
Pre-menopausal	119	18 (78)	101 (71)	NS
Post-menopausal	39	5 (22)	34 (24)	
Unknown	9	0 (0)	9 (5)	
T stage (prior to CT)				
T1	9	2(9)	7 (5)	NS
T2	87	13(57)	74(51)	
T3	62	7(30)	55 (38)	
T4	9	1(4)	8(6)	
pN stage (prior to CT)				
pN0 (SNB-)	30	5 (22)	25 (17)	NS
pN1 (SNB+/FNA+)	110	15 (65)	95(66)	
pN3 (sub/supraclavicular)	11	0 (0)	11 (8)	
pNX (cN0)	16	3 (13)	13 (19)	
Histology				
Ductal	131	14 (61)	117 (81)	0.008
Lobular	20	8 (35)	12 (8)	
Others	16	1 (4)	15 (11)	
Grade				
I	7	3 (13)	6 (3)	0.011
II	88	16 (70)	72(50)	
III	66	3 (13)	63 (44)	
missing	6	1(4)	5 (3)	
Subtype (based on receptor status)				
ER+ (ER+ , HER2-)	88	21 (91)	67 (47)	<0.001
TN (ER-, PR-, HER2-)	38	0 (0)	38 (26)	
HER2+	41	2 (9)	39(27)	
Primary systemic therapy				
Antracycline-like	85	10(43)	75 (52)	0.036
Antracycline-taxane	31	9 (39)	22 (15)	
Capectabine/docetaxel	14	2(9)	12 (8)	
PTC	37	2(9)	35 (25)	
Surgery breast				
No surgery <sup>a</sup>	1	0	1 (1)	NS
Mastectomy	81	10 (44)	71 (49)	
BCS	85	13 (56)	72 (50)	

The nodal status was determined prior to chemotherapy (CT) with ultrasound guided fine-needle aspiration (FNA) and sentinel node biopsy (SNB). pNX: no pathological nodal status  
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; NS, not significant ( $P > 0.05$ )

Antracycline-like: cyclophosphamide doxorubicine (AC). Antracycline-taxane: AC→ capecitabine docetaxel (CD) or cyclophosphamide/docetaxel (AD). PTC: paclitaxel/trastuzumab/carboplatin. BCT: breast conserving surgery

<sup>a</sup> Due to progression mastitis carcinomatosa only radiation therapy


20% (29/144;  $P = 0.015$ ; Fig. 1). Furthermore, we assessed chemosensitivity by separately analyzing the pathological response of the primary tumor in the breast (pCR and near-pCR). In the good prognosis-signature group, 2 of the 23 patients achieved a near-pCR of the primary tumor (9%). In the poor prognosis-signature group the pathological response was 37% (53/144;  $P = 0.008$ ). Figure 2 shows the relation between the classification of

the 70-gene profile as a continuous variable and pCR. Patients with a low MammaPrint Index have a higher probability to achieve a pCR.

The pathological response (breast and axilla) was also analyzed in subgroups that were characterized according to receptor status of the tumor (Table 2). In ER-positive (HER2-), triple-negative and HER2-positive tumors the pCR rates were different; 3% (3/88), 34% (13/38) and 32%

**Fig. 2** The association between the classification of the 70-gene prognostic signature and the pathological response.

Classification of the 70 gene prognosis signature of each sample is plotted. Tumors are ordered by their correlation to the average profile of the good prognosis group. Patients with a pCR are indicated by *black dots* and patients without a pCR are indicated by *white dots*



**Table 2** The response in three subtypes characterized by receptor status

	Subtype			
	ER+/HER2- (n = 88)	TN- (n = 38)	HER2+ <sup>a</sup> (n = 41)	Total (n = 167)
	No. (%)	No. (%)	No. (%)	No. (%)
Response breast + axilla				
pCR	3 (3)	13 (34)	13 (32)	29 (17)
Response breast				
pCR	6 (7)	17 (45)	17 (42)	40 (24)
npCR	7 (8)	2 (5)	6 (15)	15 (9)

The response rate differed significantly between the subtypes. ( $P < 0.001$ )

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative (estrogen, progesterone and HER2 negative); pCR, pathological complete remission; npCR, near pCR

<sup>a</sup> Four patients did not receive trastuzumab

(13/41), respectively, ( $P < 0.001$ ). Among the ER-positive (HER2-) patients, 21/88 (24%) were classified as having a good prognosis-signature and 67/88 patients (76%) were classified as having a poor prognosis-signature (Fig. 3). None of the ER-positive patients with a good prognosis-signature achieved a pCR and all three patients who did, had a tumor with a poor prognosis-signature. Of the HER2-positive patients, 2/41 (5%) were classified as good prognosis-signature and 39/42 (95%) as having a poor prognosis-signature. Both HER2-positive patients with a good prognosis-signature were also ER-positive and both did not

achieve a pCR. Among the HER2-positive patients with a poor prognosis-signature the pCR rate was 33% (13/39). None of the triple negative tumors in this study ( $n = 38$ ) had a good prognosis-signature. We, therefore separately analyzed the predictive power of the 70 gene signature in the subgroup comprising all ER-positive and/or HER2-positive tumors. Thus, we excluded the patients with triple negative tumors which all had a poor prognosis-signature. In this non-triple negative subgroup the pCR rate in good and poor prognosis-signature tumors was 0% (0/23) and 15% (16/106), respectively, ( $P = 0.07$ ). When the response of the primary tumor was assessed separately, a significant association between the response and the result of the 70-gene profile could be shown. Pathological response, pCR or near-pCR of the primary tumor, was achieved in 9% (2/23) of the patients with a good prognosis-signature tumor and in 32% (34/106) of the patients having a poor prognosis-signature tumor ( $P = 0.023$ ).



After a median follow up of 25 months (range: 5–91), 17 patients had a relapse. These included local recurrences in 2 patients and distant metastases in 15 patients. None of the patients with a good prognosis-signature had a relapse. The disease-free survivals are shown in Fig. 4 ( $P = 0.066$ ).

## Discussion

To prospectively assess the predictive value of a prognostic marker, large and logistically challenging clinical trials are required, that—in case of node-negative breast



**Fig. 3** The distribution of the three different subtypes characterized by receptor status within good and poor prognosis patients. All patients with triple negative tumors had a tumor with a poor prognosis-signature. We, therefore, separately analyzed the predictive power of the 70 gene signature in the subgroup including ER-positive and HER2-positive tumors. Response of the breast is defined pathological complete remission (pCR) or near pCR



**Fig. 4** The disease-free survival of the good and poor prognosis patients separately. The median follow up was 25 months and 17 relapses occurred in the poor prognosis group

cancer—may take decades to accumulate sufficient events for a useful analysis. An alternative and more rapid approach is to evaluate the predictive value of a prognostic marker for chemosensitivity in the neoadjuvant setting. Here, the pathological response can be used as endpoint, since the achievement of pCR has gained wide acceptance as a predictor of a good long-term prognosis [20, 21].

In this report a series of 167 patients with stage II and III primary invasive breast cancer who received neoadjuvant chemotherapy is described. Although several types of chemotherapy were used, most patients were treated with an anthracycline-based regimen. The proportion of tumors with a good 70-gene prognosis-signature was 14%, which

is less than the percentage (38 and 41%) reported in earlier series of node-positive patients. This is likely the result of the inclusion criteria which intentionally selected clinically higher-risk patients, with larger tumors and/or axillary lymph node involvement, for neoadjuvant chemotherapy.

We observed that tumors with a poor prognostic 70-gene signature are more likely to achieve a complete response than those with a good prognostic signature. Even if the triple-negative tumor subgroup was excluded, which is usually associated with a relatively high pCR rate and in this current study with an invariably poor prognosis 70-gene profile, the response to chemotherapy remained significantly higher in the poor prognosis-signature tumors. This strongly suggests that the 70-gene profile has predictive power with respect to chemosensitivity.

The absence of ER expression and poor differentiation, tumor characteristics more often seen in the poor signature group, are generally believed to be associated with a higher likelihood of response to chemotherapy [1]. Molecular subtypes such as luminal, basal, ERBB2 and normal-like subtypes, differ markedly with respect to prognosis, with a basal-like subtype having a worse prognosis than a luminal subtype [22]. To a degree, these molecular subtypes can be also be distinguished using immunohistochemistry [23]. Carey et al. [24] classified tumors of a series of patients undergoing neoadjuvant therapy in basal-like, luminal and ERBB2-like molecular subtypes using immunohistochemical staining of the hormone and HER2 receptors. A significantly different response to neoadjuvant chemotherapy was observed in these subtypes. Basal-like tumors (i.e. triple negative) had a higher pCR rate compared to luminal subtypes which express the estrogen receptor. Our study confirms these findings, with a higher pCR rate in triple negative tumors as compared to ER-positive tumors. Since

all triple negative tumors had a poor prognosis-signature, it was expected that the pCR rate would be higher in the poor signature group. Nevertheless, the predictive value remained after exclusion of the triple negative tumors, suggesting additional predictive value for the 70-gene signature.

Another prognostic gene expression test, the 21-gene recurrence score (Oncotype DX<sup>®</sup> assay) has been correlated with pCR in the neoadjuvant setting [25]. Subsequently, Paik et al. [26] retrospectively assessed its predictive value for ER-positive patients in the adjuvant setting. They showed that the neoadjuvant result was confirmed in the adjuvant setting, as a high recurrence score was associated with relatively greater benefit from adjuvant cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy in patients with ER-positive, lymph node-negative disease.

Despite the proven predictive value of pCR in neoadjuvant trials, there is no consensus on the measurement of this important endpoint. Absence of tumor cells in both the axilla and breast is the most stringent definition and was therefore primarily used in this study. On the other hand, we believe that a reduction of tumor load of the primary tumor to single scattered tumor cells may also imply chemosensitivity. To gain more insight in chemosensitivity we separately assessed the responses of the primary tumors according to this frequently used definition. However, longer follow-up will be required to confirm that the eradication of a large number of tumor cells is associated with long-term survival.

In conclusion, this study shows that tumors with a poor 70-gene signature are more likely to achieve a pCR, whereas tumors with a good prognosis-signature are not. This finding has several important clinical implications. Currently, the 70 gene profile is used to select patients for adjuvant chemotherapy whereby chemotherapy is frequently withheld for tumors with a good prognosis-signature [27]. Our results add justification to this policy; not only is the absolute risk of relapse lower in these patients, but their tumors are also less sensitive to chemotherapy. For the good prognosis signature group, this may lead to a significantly lower proportional risk reduction than suggested in the Oxford overview or in the frequently used Adjuvant! Online program [28]. We also believe that the stratification of subjects according to the 70-gene profile could be helpful in controlled trials investigating the effectiveness of new drugs or new combinations of drugs.

**Conflicts of interest** This study was financially supported by Agendia, the commercial company that markets the 70-gene signature as MammaPrint. L. van 't Veer is a shareholder in and (part time) employed by Agendia. A.M. Glas is employed by Agendia.

## References

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687–1717
2. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415:530–536
3. Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, van't Veer LJ, van de Vijver MJ (2008) Validation of 70-gene prognosis signature in node-negative breast cancer. *Breast Cancer Res Treat*. doi:10.1007/s10549-008-0191-2
4. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *J Natl Cancer Inst* 98:1183–1192
5. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, van't Veer LJ (2008) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study. *Breast Cancer Res Treat*. doi:10.1007/s10549-008-0130-2
6. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 347:1999–2009
7. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. *J Clin Oncol* 26:729–735
8. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ (2005) Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. *J Clin Oncol* 23:3331–3342
9. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19:403–410
10. Hauser-Kronberger C, Dandachi N (2004) Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. *J Mol Histol* 35:647–653
11. Citron ML, Berry DA, Cirincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. *J Clin Oncol* 21:1431–1439
12. Lebowitz PF, Eng-Wong J, Swain SM, Berman A, Merino MJ, Chow CK, Venzon D, Zia F, Danforth D, Liu E, Zujewski J (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. *Clin Cancer Res* 10:6764–6769



13. O'Shaughnessy JA, Blum JL (2006) Capecitabine/taxane combination therapy: evolving clinical utility in breast cancer. *Clin Breast Cancer* 7:42–50
14. Burris HIII, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. *J Clin Oncol* 22:1621–1629
15. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-over-expressing metastatic breast cancer: NCCTG study 983252. *Clin Breast Cancer* 6:425–432
16. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hanne-mann J, Muller SH, Peeters MJ, Gilhuijs KG (2008) Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. *AJR Am J Roentgenol* 191:1331–1338
17. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. *Proc Natl Acad Sci U S A* 100:15901–15905
18. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, van't Veer LJ (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. *BMC Genomics* 7:278
19. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. *J Clin Oncol* 25:2650–2655
20. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. *J Clin Oncol* 26:778–785
21. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. *J Clin Oncol* 19:4224–4237
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. *Nature* 406:747–752
23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clin Cancer Res* 10:5367–5374
24. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. *Clin Cancer Res* 13:2329–2334
25. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. *J Clin Oncol* 23:7265–7277
26. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol* 24:3726–3734
27. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). *Lancet Oncol* 8:1079–1087
28. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. *J Clin Oncol* 19:980–991